Most people who have their bladder removed for cancer survive at least five years, though the number depends heavily on how advanced the cancer was at the time of surgery. For cancer confined to the bladder wall, the five-year cancer-specific survival rate is around 85%. For cancer that has grown into surrounding tissue, that drops to roughly 51%, and for the most advanced cases it falls to about 18%. These aren’t hard limits on lifespan. They’re population averages, and many people live well beyond them.
Survival Rates by Cancer Stage
Stage is the single biggest factor in how long you can expect to live after bladder removal (radical cystectomy). When cancer is caught while still contained within the muscle layer of the bladder, five-year overall survival sits around 81%, with cancer-specific survival at 85%. “Cancer-specific” means it only counts deaths caused by bladder cancer itself, filtering out unrelated causes like heart disease.
Once cancer has spread beyond the bladder into nearby fat or tissue, those numbers roughly halve. Five-year overall survival drops to about 49%, and cancer-specific survival to 51%. For tumors that have invaded neighboring organs, overall survival at five years falls to around 11%, with cancer-specific survival at 18%. The gap between overall and cancer-specific survival at every stage reflects the reality that many patients are older adults dealing with other health conditions simultaneously.
Looking further out, one large study found that 10-year overall survival across all stages was 43.4%, with cancer-specific survival at 47.2%. So nearly half of all patients were still alive a decade after surgery, which is encouraging given that most people undergoing this operation have aggressive disease.
Lymph Node Status Changes the Picture
Whether cancer has reached the lymph nodes matters almost as much as stage. In patients with no lymph node involvement, five-year overall survival was 67.2%, and cancer-specific survival was 70.7%. When lymph nodes tested positive for cancer, those numbers dropped sharply to 13.9% and 15.1%, respectively. At the two-year mark, the split was already visible: 81.2% survival for node-negative patients versus 46.9% for node-positive patients.
The thoroughness of the lymph node removal during surgery also plays a role. Research involving over 3,000 patients found that among people whose lymph nodes were cancer-free, those who had more nodes removed during surgery had better overall and disease-specific survival. The likely explanation is that removing more nodes reduces the chance of missing microscopic cancer deposits.
Age and Overall Health
Bladder removal is a major operation, and your body’s ability to recover from it and handle potential complications shapes long-term outcomes. Patients over 70 and those with multiple existing health conditions (scored using a comorbidity index) face meaningfully lower survival. One study found that patients in the 71 to 76 age range had more than double the death rate compared to younger patients after adjusting for cancer characteristics. A high burden of other illnesses, such as diabetes, heart disease, or lung conditions, independently increased the risk of death by about 61%.
This doesn’t mean older patients shouldn’t have the surgery. It means age and overall fitness are important factors in the conversation about what to expect afterward.
The First Two Years Are Critical
If bladder cancer is going to come back after surgery, it usually does so early. The median time to recurrence is roughly 10 to 12 months, with most recurrences happening within the first two years. The average across studies is about 14.6 months, though the range stretches from 2 months to over 4 years. People with more advanced disease at the time of surgery tend to recur faster: patients with later-stage tumors had a mean recurrence time of about 13 months compared to nearly 23 months for those with earlier-stage disease.
Overall recurrence risk ranges from 5% to 70% depending on stage. This wide range underscores why stage matters so much. If you make it past the two-year mark without recurrence, your outlook improves considerably, though ongoing monitoring remains important.
Chemotherapy’s Role in Survival
Receiving chemotherapy before surgery (neoadjuvant chemotherapy) has been shown to improve five-year overall survival by 5% to 7% compared to surgery alone. That may sound modest, but in a disease where margins matter, it’s considered a meaningful benefit and is now the standard recommendation for eligible patients with muscle-invasive bladder cancer. Chemotherapy given after surgery is also used in some cases, particularly when pathology results reveal more advanced disease than expected.
Life With Urinary Diversion
After the bladder is removed, urine has to go somewhere. The two most common options are an ileal conduit (where urine drains through a small opening in your abdomen into an external bag) and a neobladder (a new internal reservoir constructed from a segment of intestine). About 60% of patients receive an ileal conduit, and roughly 40% get a neobladder.
Initial analyses suggested neobladder patients had better disease-free and overall survival, but when researchers adjusted for differences in age, cancer stage, and other factors between the two groups, the survival advantage disappeared. The type of diversion you receive does not independently affect how long you live. The choice is more about quality of life and functional preferences than survival.
One long-term concern with any urinary diversion is kidney health. Nearly 59% of patients with an ileal conduit developed chronic kidney disease in one study, compared to about 18% of healthy controls. The prevalence of kidney problems after diversion ranges from 10% to 60% across different research. Active monitoring of kidney function after surgery helps catch and manage decline before it becomes severe.
Surviving the Surgery Itself
Radical cystectomy carries real short-term risks. The 30-day mortality rate at experienced centers is about 1.3%, rising to 4.9% at 90 days. Early complications occur in roughly a third of patients, and late complications (developing months to years later) affect about 42%. These numbers have remained relatively consistent over the past two decades, even as surgical techniques have improved, largely because the patient population tends to be older with more health conditions.
Robotic-assisted surgery has become increasingly common and may reduce some short-term complications, though long-term survival outcomes are comparable to open surgery. Hospital and surgeon experience with the procedure is one of the more important variables in reducing perioperative risk.